Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

This study has been completed.
Dana-Farber Cancer Institute
Genentech, Inc.
Bristol-Myers Squibb
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Harvard Vanguard Medical Associates
Brigham and Women's Hospital
Information provided by (Responsible Party):
Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute Identifier:
First received: August 26, 2005
Last updated: February 15, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2012
  Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)